Printer Friendly

Articles from M2 Pharma (September 21, 2017)

1-21 out of 21 article(s)
Title Author Type Words
Amarin names new chief commercial officer. 124
Aquagenx Launches New Quantitative Water Quality Test for Hydrogen Sulfide Bacteria. 206
Arbor Pharmaceuticals Releases Lower Dose Nymalize (nimodipine) Oral Solution for Treatment of Subarachnoid Hemorrhage. 225
Arvinas Names Dr. John Houston as President and CEO. 224
Avita Medical secures USD24.3m in expanded contract option. 180
Bio-Techne Launches 32x4 Sample Cartridge for Immunoassay Platform. 467
DelMar expects USD10m from direct at-the-market offering. 202
DelMar Pharmaceuticals Eyes USD 10m Raise from Registered Direct Offering. 402
European Commission approves Ipsen's Xermelo. 171
FDA Grants Orphan Drug Designation to PhaseRx for PRX-ASL for Treatment of Argininosuccinate Lyase Deficiency. 296
M3 names new director of education. 185
Merck KGaA & Pfizer Inc partnership win EC's marketing authorisation for BAVENCIO for metastatic merkel cell carcinoma. 317
MYOS RENS elects Joseph Mannello as permanent CEO. 159
Myos Rens Names Joseph Mannello as Permanent CEO. 219
NIDCR Awards Soligenix USD 1.5m SBIR Grant for Clinical Trial of SGX942 for Treatment of Oral Mucositis. Clinical report 485
SonaCare Medical reports growth in ASC payment for HIFU device-intensive procedure in prostate ablation. 182
Southern Research, UTHSC Drug Discovery Collaboration Targets Novel Treatments Against Diseases. 532
Study Finds Heroin-Positive Patients Have Increasing Co-Occurrence of Non-Prescribed Fentanyl. 434
Study Finds that Microbiome Manipulation Decelerates Osteoarthritis Progression. 419
USPTO Grants Pulmatrix Patents on Inhaled Drug Delivery Technology and COPD Drug. 360
USPTO Issues AOBiome Patent for Ammonia Oxidizing Bacteria for Treatment of Acne. Clinical report 355

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters